Business Context and Reporting Period
Company: Abbott Laboratories
Filing Type: Form 8-K (Current Report)
Date of Report: July 17, 2013
Reporting Period: Second Quarter 2013
This filing announces the results of operations for the second quarter of 2013. The report incorporates a press release (Exhibit 99.1) by reference, which contains the detailed financial data.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing serves as a notification of the results rather than a detailed financial statement.
Non-GAAP Measures: The company utilizes non-GAAP financial measures to adjust for unusual or unpredictable factors, including:
- Costs related to the separation of the research-based pharmaceuticals business (AbbVie Inc.).
- Interest expense adjustments reflecting the post-separation capital structure.
- Cost reduction initiatives.
- Tax expense adjustments for 2013 U.S. tax law changes.
- Acquired in-process research and development and milestone payments.
- Restructuring and integration costs.
- Intangible amortization expense.
Material Changes
The filing text does not provide specific comparative data or quantify material changes versus the prior comparable period. It notes that the results are furnished via an external press release.
Guidance, Outlook, and Risks
Management Commentary: Management states that non-GAAP measures provide useful information for evaluating ongoing business performance and are used internally to monitor business performance. However, the company cautions investors to consider these measures in addition to, and not as a substitute for, GAAP financial measures.
Contingencies: The filing highlights the ongoing separation of the research-based pharmaceuticals business into AbbVie Inc. as a significant factor influencing financial adjustments.
Investor Verification Checklist
- Review the full text of the Press Release (Exhibit 99.1) for specific revenue, earnings, and cash flow figures.
- Verify the reconciliation between GAAP and non-GAAP financial measures to understand the impact of the AbbVie separation.
- Assess the specific costs attributed to restructuring and integration related to the business split.
- Confirm the impact of 2013 U.S. tax law changes on the effective tax rate.